BRYXTA 300 INJECTION 12 ML

BRYXTA 300 INJECTION 12 ML is a recombinant monoclonal antibody that belongs to the immunotherapy class of cancer treatment. It can either be used as monotherapy or in combination with chemotherapy or immunotherapy medications to improve the overall survival rate.

While for women with reproductive potential subjected to BRYXTA 300 INJECTION 12 ML, it is advised to discuss with your doctor regarding the effective birth control methods during the treatment. Also to be continued for a minimum of 6 months after the treatment course completion as this medicine may impair fertility.

BRYXTA 300 INJECTION 12 ML is associated with increased risk of bleeding complications and poor wound healing. Hence it is suggested to avoid planning for surgery and maintain an interval of 28days before or after surgery.

All the side effects that are relatively caused by BRYXTA 300 INJECTION 12 ML occur until the drug concentration stays in the body. It is found that this medicine will be contained in our body for almost 4 months after the final dose.

BRYXTA 300 INJECTION 12 ML is given intravenously through infusion and the amount of drug will be measured based on the patient’s body weight, height and age. The first dose will be administered for 90 minutes and if well tolerated the infusion time can be reduced to 30 minutes.

Inform your physician before starting your treatment with BRYXTA 300 INJECTION 12 ML in case, if you are pregnant or planning for pregnancy as this medicine may cause harm to the unborn baby and interrupt the formation of blood vessels.

There is no known interaction of BRYXTA 300 INJECTION 12 ML with other drugs.

It is vital to inform your physician before taking BRYXTA 300 INJECTION 12 ML if you have the following conditions: Have conditions involving inflammation in the stomach (ulcer, colitis). Experience allergic reactions to BRYXTA 300 INJECTION 12 ML or its ingredients. Have recently undergone surgery as it is associated with the risk of bleeding. Have diabetes, hypertension, or heart problems.

Bevacizumab is a molecule used for making BRYXTA 300 INJECTION 12 ML. It is a monoclonal antibody that targets angiogenesis, the process of new blood vessel formation that is essential for cancer cell growth and spread.

BRYXTA 300 INJECTION 12 ML is primarily used in Oncology, meaning it is prescribed for the treatment of cancer. It can help in treating a variety of cancers, including colorectal cancer, lung cancer, brain cancer, kidney cancer and ovarian cancer.